Prothena to Cut Jobs, End Drug Trial After Missed Endpoints

Dow Jones

2025/05/24

By Katherine Hamilton

Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints.

The Irish biotechnology company is planning a "substantial" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said.

Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said.

Due to the results, Prothena said it would end the trial.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 23, 2025 16:25 ET (20:25 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537152321"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537152321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537152321?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-24 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537152321","market":"other","top_or_hot":-1,"title":"Prothena to Cut Jobs, End Drug Trial After Missed Endpoints","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n</p>\n<p>\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n</p>\n<p>\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n</p>\n<p>\n  Due to the results, Prothena said it would end the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena to Cut Jobs, End Drug Trial After Missed Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena to Cut Jobs, End Drug Trial After Missed Endpoints\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-24 04:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n</p>\n<p>\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n</p>\n<p>\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n</p>\n<p>\n  Due to the results, Prothena said it would end the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRTA","symbol_name":"Prothena Corporation plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537152321","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537152321","pubTimestamp":1748031900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints.The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said.Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said.Due to the results, Prothena said it would end the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRTA":"Prothena Corporation plc","BK4139":"生物科技"},"translate_title":"Prothena将裁员，在未达到终点后结束药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. \n\n\n  The Irish biotechnology company is planning a \"substantial\" job cut as it aims to decrease expenses, Chief Executive Daniel Welch said Friday. It is also evaluating business options, and will provide more details on the cuts in June, he said. \n\n\n  Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, the company said. The study also failed to meet the secondary endpoints of a 6-minute walk test distance and short-form-36 version 2 physical component score, Prothena said. \n\n\n  Due to the results, Prothena said it would end the trial. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}